 <h1>Opdivo Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>nivolumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about nivolumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Opdivo.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to nivolumab: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, nivolumab (the active ingredient contained in Opdivo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking nivolumab:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>chest tightness</li>
<li>chills</li>
<li>constipation</li>
<li>cough</li>
<li>depressed mood</li>
<li>diarrhea</li>
<li>dry skin and hair</li>
<li>fainting</li>
<li>fast, slow, pounding, or irregular heartbeat or pulse</li>
<li>feeling cold</li>
<li>feeling of warmth</li>
<li>fever</li>
<li>hair loss</li>
<li>headache</li>
<li>hoarseness or husky voice</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>loss of appetite</li>
<li>muscle cramps and stiffness</li>
<li>nausea</li>
<li>palpitations</li>
<li>red, irritated eyes</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>dark urine</li>
<li>general feeling of discomfort or illness</li>
<li>light-colored stools</li>
<li>nervousness</li>
<li>pain</li>
<li>sensitivity to heat</li>
<li>stomach cramps</li>
<li>sweating</li>
<li>tenderness</li>
<li>thickening of bronchial secretions</li>
<li>trouble sleeping</li>
<li>upper right abdominal or stomach pain</li>
<li>watery or bloody diarrhea</li>
<li>weight loss</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloating</li>
<li>bloody or cloudy urine</li>
<li>blurred vision or other change in vision</li>
<li>darkening of the skin</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>eye pain</li>
<li>fruity breath odor</li>
<li>increased hunger, thirst, and urination</li>
<li>indigestion</li>
<li>mental depression</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>redness of the eye</li>
<li>sensitivity of the eyes to light</li>
<li>skin rash</li>
<li>swelling of the face, feet, or lower legs</li>
<li>tearing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Feeling of constant movement of self or surroundings</li>
<li>lightheadedness</li>
<li>sensation of spinning</li>
<li>very deep pain in the eyes</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of nivolumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Stuffy or runny nose</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Increase in blood flow to the whites of the eyes</li>
<li>seeing flashes or sparks of light</li>
<li>seeing floating spots before the eyes or a veil or curtain appearing across a part of vision</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to nivolumab: intravenous solution</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (21%), pruritus (19%), vitiligo (11%), erythema (10%)</p>
<p><b>Frequency not reported</b>: Exfoliative dermatitis, erythema multiforme, vitiligo, psoriasis, immune-mediated rash<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated AST (28%), elevated alkaline phosphatase (22%), elevated ALT (16%)</p>
<p><b>Common</b> (1% to 10%): Elevated total bilirubin, immune-mediated hepatitis</p>
<p><b>Frequency not reported</b>: Increased amylase, increased lipase<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea or colitis (21%)</p>
<p><b>Common</b> (1% to 10%): Immune-mediated colitis, nausea, vomiting</p>
<p><b>Frequency not reported</b>: Immune-mediated pancreatitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (17%), upper respiratory tract infection (17%)</p>
<p><b>Common</b> (1% to 10%): Pneumonitis, immune-mediated pneumonitis, dyspnea<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased serum creatinine (13%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Immune-mediated nephritis, immune-mediated renal dysfunction<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (10%)</p>
<p><b>Frequency not reported</b>: Ventricular arrhythmia<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse reaction in clinical trials was rash; a composite term including the following rashes maculopapular, erythematous, pruritic, follicular, macular, papular, pustular, vesicular, and dermatitis acneiform.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism, hyperthyroidism</p>
<p><b>Frequency not reported</b>: Immune-mediated hypopituitarism, immune-mediated hypophysitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Dizziness, peripheral and sensory neuropathy, immune-mediated demyelination, immune-mediated facial and abducens nerve paresis, immune-mediated myasthenic syndrome, immune-mediated encephalitis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Infusion-related reactions<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Iridocyclitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (28%)</p>
<p><b>Frequency not reported</b>: Immune-mediated adrenal insufficiency, immune-mediated diabetic ketoacidosis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune-mediated uveitis, immune-mediated autoimmune neuropathy, immune-mediated Guillain-Barre Syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (32%), back pain (21%), arthralgia (20%)</p>
<p><b>Frequency not reported</b>: Pain in extremity<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (49%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb, Princeton, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long does it prolong life and what’s the success rate?</li>
<li>How long does it take to work and how do you know if it's working?</li>
<li>What is the difference between Opdivo and Keytruda?</li>
<li>What happens when you stop taking this for melanoma?</li>
<li>Pembrolizumab vs. nivolumab: how do they compare?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Opdivo (nivolumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>49 Reviews</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Opdivo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Esophageal Carcinoma</li>
<li>Head and Neck Cancer</li>
<li>Hepatocellular Carcinoma</li>
<li>Colorectal Cancer</li>
<li data-more-config-id="list-data-resources-conditions">... +8 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to nivolumab: intravenous solution</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (21%), pruritus (19%), vitiligo (11%), erythema (10%)</p><p><b>Frequency not reported</b>: Exfoliative dermatitis, erythema multiforme, vitiligo, psoriasis, immune-mediated rash<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated AST (28%), elevated alkaline phosphatase (22%), elevated ALT (16%)</p><p><b>Common</b> (1% to 10%): Elevated total bilirubin, immune-mediated hepatitis</p><p><b>Frequency not reported</b>: Increased amylase, increased lipase<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea or colitis (21%)</p><p><b>Common</b> (1% to 10%): Immune-mediated colitis, nausea, vomiting</p><p><b>Frequency not reported</b>: Immune-mediated pancreatitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (17%), upper respiratory tract infection (17%)</p><p><b>Common</b> (1% to 10%): Pneumonitis, immune-mediated pneumonitis, dyspnea<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased serum creatinine (13%)</p><p><b>Uncommon</b> (0.1% to 1%): Immune-mediated nephritis, immune-mediated renal dysfunction<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (10%)</p><p><b>Frequency not reported</b>: Ventricular arrhythmia<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse reaction in clinical trials was rash; a composite term including the following rashes maculopapular, erythematous, pruritic, follicular, macular, papular, pustular, vesicular, and dermatitis acneiform.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothyroidism, hyperthyroidism</p><p><b>Frequency not reported</b>: Immune-mediated hypopituitarism, immune-mediated hypophysitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Dizziness, peripheral and sensory neuropathy, immune-mediated demyelination, immune-mediated facial and abducens nerve paresis, immune-mediated myasthenic syndrome, immune-mediated encephalitis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Infusion-related reactions<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Iridocyclitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (28%)</p><p><b>Frequency not reported</b>: Immune-mediated adrenal insufficiency, immune-mediated diabetic ketoacidosis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune-mediated uveitis, immune-mediated autoimmune neuropathy, immune-mediated Guillain-Barre Syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (32%), back pain (21%), arthralgia (20%)</p><p><b>Frequency not reported</b>: Pain in extremity<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (49%)</p><p><b>Common</b> (1% to 10%): Pyrexia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb, Princeton, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long does it prolong life and what’s the success rate?</li>
<li>How long does it take to work and how do you know if it's working?</li>
<li>What is the difference between Opdivo and Keytruda?</li>
<li>What happens when you stop taking this for melanoma?</li>
<li>Pembrolizumab vs. nivolumab: how do they compare?</li>
</ul><h2>More about Opdivo (nivolumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>49 Reviews</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Opdivo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Esophageal Carcinoma</li>
<li>Head and Neck Cancer</li>
<li>Hepatocellular Carcinoma</li>
<li>Colorectal Cancer</li>
<li data-more-config-id="list-data-resources-conditions">... +8 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>